Genentech/Roche's Avastin fails Phase III study in early-stage colon cancer
This article was originally published in Scrip
Executive Summary
Genentech/Roche's anti-angiogenic monoclonal antibody Avastin (bevacizumab) has failed to meet the primary endpoint of disease-free survival in its Phase III trial of use as adjuvant therapy in early-stage colon cancer.